Market Overview

UPDATE: Stifel Nicolaus Raises PT to $9 on Boston Scientific Corporation Post Analyst Day

Related BSX
Boston Scientific Begins Clinical Trial of ACUITY X4 LV Pacing Leads and RELIANCE 4-FRONT ICD Leads
Wednesday IPO Review & Sneak-Peek For Thursday, April 17

Stifel Nicolaus maintained Boston Scientific Corporation (NYSE: BSX) with a Buy rating and raised the price target from $8.00 to $9.00.

Stifel Nicolaus noted, "We left yesterday's Boston Scientific New York Analyst Day believing our basic thesis on BSX shares is unchanged. If anything, we left with increased conviction that after three years of negative top-line growth, BSX now has in place multiple avenues to re-accelerate sales growth back to mid-single digits by the 2016-2017 time frame. … Also evident throughout the meeting was the strong management team now in place at BSX and their clear and energetic strategic vision for the company. Overall, management laid out what we thought was a well thought-out and realistic plan to improve the growth and profitability prospects of the company."

Boston Scientific Corporation closed at $7.59 on Tuesday.

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (BSX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free